Q4 EPS Forecast for USANA Health Sciences Reduced by Analyst

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti Csr decreased their Q4 2027 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research report issued on Wednesday, February 11th. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will earn $0.75 per share for the quarter, down from their prior estimate of $0.76. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share.

USNA has been the subject of a number of other research reports. Zacks Research cut USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Two research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Stock Down 1.2%

NYSE USNA opened at $20.89 on Friday. USANA Health Sciences has a fifty-two week low of $18.48 and a fifty-two week high of $38.32. The business has a fifty day moving average of $20.66 and a 200-day moving average of $23.91. The stock has a market cap of $381.92 million, a price-to-earnings ratio of 23.74, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67.

Institutional Trading of USANA Health Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. National Bank of Canada FI increased its stake in shares of USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after acquiring an additional 1,201 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in USANA Health Sciences by 382.5% in the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares during the period. CWM LLC grew its holdings in USANA Health Sciences by 109.7% in the second quarter. CWM LLC now owns 2,762 shares of the company’s stock valued at $84,000 after purchasing an additional 1,445 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in USANA Health Sciences by 52.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock worth $106,000 after purchasing an additional 1,327 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in USANA Health Sciences by 1,354.3% during the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after purchasing an additional 3,589 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.